Denmark's Genmab expands biotech collaboration with Janssen
COPENHAGEN (Reuters) - Danish biotech company Genmab on Wednesday announced an expansion of its Duobody antibody technology collaboration with Janssen Biotech, a part of Johnson & Johnson.
Genmab said it will receive an initial payment of $2 million and potentially will be entitled to milestone and license payments of as much as $174 million to $219 million for each of ten additional programmes.
(Reporting by Teis Jensen; Editing by David Goodman)
- Mexican train derails, stranding 1,300 migrants headed toward U.S.
- Israeli strikes kill more Palestinians; rocket causes huge blaze in Israel |
- Four servicemen, five miners killed in eastern Ukraine |
- Man charged with killing six members of same Texas family |
- Taliban sympathizer posts pictures of smiling Bowe Bergdahl
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video